“Results from KEYNOTE-177 after 5 years: innovation in treating metastatic colorectal cancer with MSI-H/dMMR. This study confirms the transformative impact of pembrolizumab as a first-line treatment, marking a turning point in oncologic care:
– Progression-free survival (PFS): 16.5 months with pembrolizumab vs. 8.2 months with chemotherapy (HR 0.60).
– Overall survival (OS): Median OS: 77.5 vs. 36.7 months (HR 0.73) and 5-year OS rates: 55% vs. 44%.
– Severe adverse events (AEs): Less frequent with pembrolizumab: 22% vs. 67%.
With sustained responses and lower toxicity, pembrolizumab doubles median OS, establishing itself as the standard of care for patients with MSI-H/dMMR metastatic colorectal cancer. This breakthrough redefines oncology practice.”
